High-resolution array-CGH analysis on 46,XX patients affected by early onset primary ovarian insufficiency discloses new genes involved in ovarian function by I. Bestetti et al.
Human Reproduction, Vol.34, No.3 pp. 574–583, 2019
Advanced Access publication on January 28, 2019 doi:10.1093/humrep/dey389
ORIGINAL ARTICLE Reproductive genetics
High-resolution array-CGH analysis on
46,XX patients affected by early onset
primary ovarian insufﬁciency discloses
new genes involved in ovarian function
I. Bestetti1,2, C. Castronovo1, A. Sironi1,2, C. Caslini2, C. Sala3,
R. Rossetti4, M. Crippa1,2, I. Ferrari4, A. Pistocchi2, D. Toniolo3,
L. Persani4,5, A. Marozzi2, and P. Finelli1,2,*
1Istituto Auxologico Italiano, IRCCS, Lab of Medical Cytogenetics and Molecular Genetics, Milan 20145, Italy 2Department of Medical
Biotechnology and Translational Medicine, University of Milan, Segrate, Milan 20090, Italy 3Division of Genetics and Cell Biology, San Raffaele
Research Institute and Vita Salute University, Milan 20132, Italy 4Istituto Auxologico Italiano, IRCCS, Division of Endocrine and Metabolic
Diseases and Lab of Endocrine and Metabolic Research, Milan 20149, Italy 5Department of Clinical Sciences and Community Health,
University of Milan, Milan 20121, Italy
*Corresponding address. Medical Cytogenetics and Molecular Genetics Lab, IRCCS Istituto Auxologico Italiano, via Ariosto 13, Milan 20145,
Italy. E-mail: ﬁnelli@auxologico.it, palma.ﬁnelli@unimi.it
Submitted on September 7, 2018; resubmitted on October 23, 2018; accepted on December 27, 2018
STUDY QUESTION: Can high resolution array-CGH analysis on a cohort of women showing a primary ovarian insufﬁciency (POI) pheno-
type in young age identify copy number variants (CNVs) with a deleterious effect on ovarian function?
SUMMARY ANSWER: This approach has proved effective to clarify the role of CNVs in POI pathogenesis and to better unveil both novel
candidate genes and pathogenic mechanisms.
WHAT IS KNOWN ALREADY: POI describes the progression toward the cessation of ovarian function before the age of 40 years.
Genetic causes are highly heterogeneous and despite several genes being associated with ovarian failure, most of genetic basis of POI still
needs to be elucidated.
STUDY DESIGN, SIZE, DURATION: The current study included 67 46,XX patients with early onset POI (<19 years) and 134 control
females recruited between 2012 and 2016 at the Medical Cytogenetics and Molecular Genetics Lab, IRCCS Istituto Auxologico Italiano.
PARTICIPANTS/MATERIALS, SETTING, METHODS: High resolution array-CGH analysis was carried out on POI patients’ DNA.
Results of patients and female controls were analyzed to search for rare CNVs. All variants were validated and subjected to a gene content
analysis and disease gene prioritization based on the present literature to ﬁnd out new ovary candidate genes. Case-control study with statis-
tical analysis was carried out to validate our approach and evaluate any ovary CNVs/gene enrichment. Characterization of particular CNVs
with molecular and functional studies was performed to assess their pathogenic involvement in POI.
MAIN RESULTS AND THE ROLE OF CHANCE: We identiﬁed 37 ovary-related CNVs involving 44 genes with a role in ovary in 32
patients. All except one of the selected CNVs were not observed in the control group. Possible involvement of the CNVs in POI pathogen-
esis was further corroborated by a case-control analysis that showed a signiﬁcant enrichment of ovary-related CNVs/genes in patients (P =
0.0132; P = 0.0126). Disease gene prioritization identiﬁed both previously reported POI genes (e.g. BMP15, DIAPH2, CPEB1, BNC1) and new
candidates supported by transcript and functional studies, such as TP63 with a role in oocyte genomic integrity and VLDLR which is involved in
steroidogenesis.
LARGE SCALE DATA: ClinVar database (http://www.ncbi.nlm.nih.gov/clinvar/); accession numbers SCV000787656 to SCV000787743.
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LIMITATIONS, REASONS FOR CAUTION: This is a descriptive analysis for almost all of the CNVs identiﬁed. Inheritance studies of
CNVs in some non-familial sporadic cases was not performed as the parents’ DNA samples were not available. Addionally, RT-qPCR ana-
lyses were carried out in few cases as RNA samples were not always available and the genes were not expressed in blood.
WIDER IMPLICATIONS OF THE FINDINGS: Our array-CGH screening turned out to be efﬁcient in identifying different CNVs pos-
sibly implicated in disease onset, thus supporting the extremely wide genetic heterogeneity of POI. Since almost 50% of cases are negative
rare ovary-related CNVs, array-CGH together with next generation sequencing might represent the most suitable approach to obtain a com-
prehensive genetic characterization of POI patients.
STUDY FUNDING/COMPETING INTEREST(S): Supported by Italian Ministry of Health grants ‘Ricerca Corrente’ (08C203_2012)
and ‘Ricerca Finalizzata’ (GR-2011-02351636, BIOEFFECT) to IRCCS Istituto Auxologico Italiano.
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Introduction
Primary ovarian insufﬁciency (POI) is a heterogeneous group of dis-
orders whose incidence increases with increasing age (1:10,000
women by age 20, and 1:100 by age 40) (Goswami and Conway,
2005). POI describes the progression toward the cessation of ovar-
ian function and can occur as either primary (PA) or secondary
amenorrhea (SA), in syndromic or non-syndromic phenotypes
(Rossetti et al., 2017). While PA represents the most severe mani-
festation of the disorder, characterized by absent pubertal develop-
ment and/or ovarian dysgenesis (OD), SA is generally associated
with milder phenotypes with a post-pubertal onset (Beck-Peccoz
and Persani, 2006; Cox and Liu, 2014). Genetic causes are highly
heterogeneous and might explain at least some of the sporadic idio-
pathic cases, which comprise 50–90% of cases (Chapman et al.,
2015). Both numerical and structural chromosomal anomalies of
which Turner’s syndrome (45,X) is the most frequent, as well as
46,XX non-syndromic patients’ genomic alterations have been so
far reported as causative of POI (Fonseca et al., 2015; Laissue,
2015; Huhtaniemi et al., 2018).
Recently, thanks to genome-wide investigation based on both single-
nucleotide polymorphism array and array comparative genomic
hybridization (array-CGH) technologies, several X-linked and auto-
somal copy number variants (CNVs) affecting loci with a possible role
in female fertility have been identiﬁed (Aboura et al., 2009; Dudding
et al., 2010; Ledig et al., 2010; Quilter et al., 2010; Knauff et al., 2011;
Zhen et al., 2013; Castronovo et al., 2014). A few high resolution stud-
ies have analyzed small groups of 46,XX non-syndromic POI patients,
either phenotypically mixed (i.e. PA, SA and infertile patients)
(McGuire et al., 2011; Norling et al., 2014; Jaillard et al., 2016) or
homogeneously affected by early menopause (Tsuiko et al., 2016).
Besides genes already known to be involved in POI pathogenesis,
other novel genes with an important role in ovarian development have
been identiﬁed and proposed as candidates. However, the low detec-
tion rate («50%) suggests that most of the genetic basis of POI still
needs to be elucidated, possibly by a complementary high throughput
genome-wide approach such as whole exome sequencing (Tsuiko
et al., 2016). In addition, the extreme degree of genetic heterogeneity
as well as the presence of multiple rare rearrangements/single nucleo-
tide variants carried by single individuals (McGuire et al., 2011; Norling
et al., 2014; Tsuiko et al., 2016) seem to be constant features of POI
genetic architecture.
Here, we performed the ﬁrst high resolution array-CGH-based
case-control investigation on a cohort of young 46,XX patients (POI
onset <19 years) homogeneously affected by PA and/or OD to iden-
tify genetic defects caused by highly penetrant variants with an earlier
deleterious effect on ovarian function. This approach has proved
effective to clarify the role of CNVs in POI pathogenesis and to better
unveil both novel candidate genes and pathogenic mechanisms.
Materials andMethods
Study design
A cohort of 46,XX patients affected by severe primary ovarian insufﬁ-
ciency was collected and screened by high resolution array-CGH analysis
to identify novel ovary-related genes involved in the POI phenotype, which
were then analyzed by disease gene prioritization to highlight the most
likely candidates. To validate our approach, a case-control study using a
cohort of fertile females was also carried out and the pathogenic effect of
some identiﬁed CNVs containing candidate genes was further investigated
at the genomic and transcript level (Fig. 1).
Figure 1 Flowchart of the study design.
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Ethical approval
Written informed consent to the research investigation, approved by the
Ethical Clinical Research Committees of IRCCS Istituto Auxologico Italiano
and of San Raffaele Research Institute, was obtained from either the adult
patients or parents of underage patients.
Patients and controls
There were 67 Caucasian patients affected by POI, mean age 19.2 ± 7.3
years (median: 16 years), were enrolled from July 2011 to December
2014. The patients were referred and gave their informed consent to the
study at the Division of Endocrine and Metabolic Diseases of Istituto
Auxologico Italiano and at the Division of Genetics and Cell Biology of San
Raffaele Research Institute in Milan. The inclusion criteria were 46,XX kar-
yotype, primary amenorrhea (61 patients) or very early secondary amen-
orrhea (6 patients) occurring immediately after menarche. Mean age at
diagnosis was 15.1 ± 1.7 years and the hormone levels in the analyzed
patients were in the postmenopausal range (FSH > 40 UI/l and estradiol
<30 pg/ml). All included patients were phenotypically normal and con-
sidered idiopathic because they did not have any POI-related conditions
such as ovarian surgery or previous chemo- or radio-therapy
(Supplementary Table SI). Patients cohort included 35 sporadic (52.23%),
and 25 familial (37.31%) POI cases; clinical details are reported in
Supplementary Table SI.
The control cohort, selected from our in-house array-CGH data of
healthy individuals, consisted of 134 healthy Caucasian women with a nor-
mal karyotype, who had given birth to at least one child, and with a mean
age of 46.5 ± 10.4 years.
Array-CGH analysis, CNV classiﬁcation and
validation
The genome scan was performed using the Human Genome CGH
Microarray Kits 1 × 244 K (9 patients) and 2 × 400 K (58 patients), accord-
ing to the manufacturer’s instructions (Agilent Technologies, Santa Clara,
CA, USA). Data were extracted and analyzed for copy number changes
using Agilent CytoGenomics v.3.0 (Agilent Technologies). CNV classiﬁca-
tion was performed according to the Database of Genomic Variants
(DGV) (http://projects.tcag.ca/variation/, release March 2016) to
exclude common polymorphic CNVs with a frequency >1% in healthy
controls. To conﬁrm the actual rarity of the CNVs identiﬁed in POI
patients, in-house array-CGH results were drawn for the female controls
previously analyzed with 244 K (n = 71) and 400 K (n = 63) platforms.
CNVs detected by ≤5 probes or with an unknown inheritance were valid-
ated by means of real-time quantitative PCR (qPCR) or Long-Range PCR
(LR-PCR). Speciﬁcally, qPCR was performed on gDNA using SYBR Green
methodology (Thermo Fisher Scientiﬁc, Waltham, MA, USA) and data
were analyzed through the 2−ΔΔCt method (Livak and Schmittgen, 2001).
LR-PCR with speciﬁc primers able to amplify the aberrations breakpoints
was carried out using TaKaRa LA TaqTM kit (TaKaRa, JP). PCR products
were sequenced using the BigDye® Terminator v3.1 Cycle Sequencing Kit
(Thermo Fisher Scientiﬁc). Electropherograms obtained were analyzed
using ChromasPro 1.5 software (Technelysium Pty Ltd., Tewantin QLD,
Australia). A full list of primers is available upon request.
Ovarian CNVs selection and classiﬁcation
In order to pick out CNVs with a putative role in POI etiology, the rare
CNVs identiﬁed in patients and controls were assessed for gene content
and compared with similar already reported CNVs using public databases
such as ISCA (https://www.clinicalgenome.org/, update November
2012), and DECIPHER v9.10 (http://www.sanger.ac.uk/PostGenomics/
decipher/, last accessed March 2017). Genes involved in rare CNVs were
analyzed in both patients and controls according to the following features:
(i) expression and function in ovary, (ii) association with POI in humans
and (iii) presence of animal models. A positive feedback in at least one out
of three evaluated features classiﬁed the genes and relative CNVs as
ovary-related. Ovarian Kaleidoscope Database (OKdb, http://okdb.
appliedbioinfo.net, last accessed July 2017) was consulted for expression,
function, and reported variants, and Mouse Genome Informatics database
(MGI, http://www.informatics.jax.org/, last accessed July 2017) was
investigated to evaluate the presence of infertile or subfertile animal
models.
Prioritization strategy
To identify the top POI candidates, we applied a prioritization strategy by
scoring the genes as reported in Table I. Based on ﬁnal ranking [1–8], the
genes were classiﬁed as ‘low score’ [1–3], or ‘high score’ [4–8] genes. This
approach was applied to both patients and controls.
Statistical analyses
Statistical analyses for the case-control study were performed by online
2 × 2 contingency table (www.vassarstats.net/odds2x2.html) for Pearson’s
Chi-square test (Chi-q) and R.3.1.0 software for Wilcoxon rank sum test.
Chi-q was used to investigate signiﬁcant differences between patients and
controls in the number of individuals having either rare CNVs or ovary-
related rare CNVs. Wilcoxon rank sum test was used to evaluate a rela-
tion between CNVs and POI disease. In detail, the total number of: (i) rare
CNVs, (ii) ovary-related rare CNVs (total number, duplications and dele-
tions) and (iii) common susceptibility variants were compared between
patients and controls. Wilcoxon rank sum test was used to match the
number of: (i) ovary-related genes [score 1–8], (ii) high score genes [4–8]
and (iii) low score genes [1–3]. Data used for statistical analyses are
reported in Supplementary Table SII. Identical rearrangements found in
........................................................................................
Table I Criteria used for gene POI association score
assessment.
Total score [0–8]
Expression and Function in ovary [score 0–3]
0 nothing reported related to ovary
1 gene expressed during oocyte/follicle development in animalsa
2 gene with a known ovarian function
3 gene with more clariﬁed ovarian function
Association to POI in humans [0–3]
0 never associated to POI
1 Reported in 1 or 2 patients with fertility defects or POI
2 Reported in more than 2 patients with POI
3 OMIM disease gene for POI
Animal model [0–1]
0 No infertile or subfertile animal models
1 Presence of infertile or subfertile animal models
Literature ovary-related [0–1]
0 Less than 5 articles related to ovarian function/POI
1 More than 5 articles related to ovarian function/POI
aExpression evaluated based on published articles or expression data from Ovarian
Kaleidoscope Database (http://okdb.appliedbioinfo.net).
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familial cases were counted as one. A P-value <0.05 assigned a statistically
signiﬁcant test.
Gene expression analysis, CNVs molecular
characterizations, and luciferase assay
Transcriptional expression of ovary-related genes was evaluated on RNA
from (i) adult ovary (Human Ovary Poly A+ RNA, Clontech), (ii) fetus
(Human Fetus, Whole Poly A+ RNA, Clontech) and (iii) peripheral blood.
cDNAs from each tissue were obtained with the High Capacity cDNA
Reverse Transcription Kit (Thermo Fisher Scientiﬁc) using 500 ng of RNAs.
PCR reactions were performed using the AmpliTaq Gold® kit (Thermo
Fisher Scientiﬁc).
For genomic characterizations of CNVs involving TP63 and VLDLR, spe-
ciﬁc primers to amplify duplication/deletion breakpoints were designed for
LR-PCR reactions (TaKaRa LA TaqTM) and sequencing; qPCR on gDNA
was carried out with SYBR-Green technology (Thermo Fisher Scientiﬁc)
for SYCE1 rearrangements. RT-qPCR reactions for TP63, VLDLR and
DIAPH2 were performed using the TaqMan method with three housekeep-
ing genes as normalizers (TBP, GUSB, and RPLP0) (Supplementary
Table SIII). The 2−ΔΔCt method was applied.
For CNVs position effect assessment using luciferase assays, we selected
both CNVs adjacent to genes with a high POI association score and CNVs
present in patients whose mRNA was available for further validations. The
only variant that met these conditions was the 9p24.2 CNV (VLDLR) on
POI-44. To characterize the regulatory activity of the predicted ENCODE
elements (Ernst et al., 2011), several ﬁreﬂy luciferase reporter plasmids
were constructed by cloning 11 DNA fragments (BglII restriction sites)
into the pGL3 promoter plasmid (Promega, USA). To characterize the
activity of the fragment INS-BglII on the VLDLR promoter, a ﬁreﬂy luciferase
reporter plasmid was constructed by subcloning the promoter from posi-
tions −1000 to +100 (HindIII restriction sites) into the promoterless
pGL3-Basic (Promega). The fragment INS-BglII was then subcloned
upstream of the VLDLR promoter through BglII restriction sites. Constructs
were transfected on both COV434 granulosa cells and HeLa using Fugene
(Invitrogen) according to the manufacturer’s instructions. After treating for
16 h, cell lysates obtained with Passive Lysis Buffer 1X (Promega) were
centrifuged and the supernatants were then assayed for luciferase activity
using the Dual Luciferase reporter Assay kit (Promega). Luminescence in
relative light units (RLU) was measured for 10 s in a Fluoroskan Ascent
instrument (Labsystems). Results were then calculated as fold induction
relative to pGL3/pGL3b wild-type expression vector.
Results
Array-CGH analysis and ovary-related CNVs
The array-CGH analysis identiﬁed a total of 1402 CNVs with an aver-
age of about 21 aberrations per patient. Based on the DGV, common
variants were excluded and 72 rare validated CNVs in 49 patients
(Supplementary Table SIV) were selected. Similarly, according to the
DGV, 118 rare validated CNVs were found in 78 controls
(Supplementary Table SIV). The analysis of rare CNVs gene content in
patients and controls selected 44 and 48 unique ovary-related genes,
respectively (Supplementary Table SV). The selected genes are
included or adjacent to 37 (51.4%) CNVs in 32 patients and to 42
(35.6%) CNVs in 38 controls (Supplementary Table SIV).
To support the pathogenic effect of the selected CNVs, all detected
ovary-related variants were exclusively identiﬁed in patients, except
for the Xp22.31 duplication involving STS also found in CTR_F097
(Supplementary Table SIV). Three CNVs are adjacent to or involve
two OMIM POI genes, and ﬁve CNVs overlap with variants previously
reported in POI patients (Supplementary Fig. S1).
Among common rearrangements counted as susceptibility loci for
POI (i.e. NAIP at 5q13.2, DUSP22 at 6p25.2, and SYCE1 at 10q26.3),
26 aberrations were found in 25 patients and 41 common aberrations
were found in 39 controls (Supplementary Table SIV). All rare and
selected common CNVs identiﬁed in patients were submitted to
ClinVar database (http://www.ncbi.nlm.nih.gov/clinvar/, July 24
2018, date last accessed; accession numbers SCV000787656 to
SCV000787743).
Gene content analysis of CNVs and disease
gene prioritization indicate potentially
relevant regions for POI
Among the 44 ovary-related genes, we identiﬁed two OMIM POI genes
(DIAPH2, POF2A, OMIM#300511; BMP15, POF4, OMIM#300510),
seven genes already associated with POI in human (BNC1, CPEB1,
PSMB1, SH3GL3, STS, TBP and ZFR2) and 35 genes either not well
or never associated with POI (Supplementary Table SV). The
expression in the ovary was conﬁrmed by RT-PCR on all selected
ovary-related genes (data not shown) and detailed information
about their function are reported in Supplementary Table SVI. The
disease prioritization strategy attributing to each gene a POI associ-
ation score [1–8] (Table I, Supplementary Table SVI) identiﬁed the
most promising candidates (Fig. 2). Similarly, 48 ovary-related
genes were identiﬁed and prioritized in controls (Supplementary
Tables SV and SVI).
Statistical analysis revealed in patients a
signiﬁcant enrichment in ovary-related CNVs
and genes
In order to validate our methodological approach and results obtained
with prioritization, a case-control analysis was performed. Chi-q test
showed that the number of patients carrying either rare CNVs (n =
49) or ovary-related CNVs (n = 32) is statistically signiﬁcantly higher
compared to the number of controls (P = 0.0386, P = 0.0065, respect-
ively) (Fig. 3A, C). Wilcoxon rank sum test did not reveal any differ-
ences in the number of rare CNVs between patients and controls (P =
0.1852); conversely the number of rare ovary-related CNVs was stat-
istically signiﬁcant (P = 0.0132), in particular for duplications (P =
0.0128). Similar results were obtained for ovary-related genes (P =
0.0126), particularly for the genes classiﬁed with the highest POI asso-
ciation score (P = 0.0192) (Fig. 3B and D). Even though the Wilcoxon
test did not reveal any difference regarding the number of previously
associated common CNVs (P = 0.2494; Fig. 3B and D), no SYCE1
deletions were detected in controls.
Pathogenic effect evaluation of particular
CNVs
The identiﬁed 161 kb paternal intragenic duplication at 3q28 in POI-8
and POI-9 (Fig. 4A) involves exons 2–9 of the longest TP63 transcript
variant (NM_003722) (Fig. 4B and C). LR-PCR and sequencing of
duplication breakpoints conﬁrmed a direct tandem orientation and the
inclusion of exon 10 (Fig. 4D), reﬁning the duplication at
chr3:189,424,338-189,592,155 (hg19). RT-PCR and sequencing
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reactions speciﬁc for exon junction 10-2 conﬁrmed that 3q28 duplica-
tion produces an aberrant transcript without disruption of the reading
frame (Fig. 4E). RT-qPCRs carried out on junction 7–8, 11–12
indicated that TP63 transcript levels in the patient are comparable to
that in controls, and only a small amount of the duplicated aberrant
mRNA is present (about 30% of the total level) (Fig. 4E). Since the
Figure 2 Schematic view of genes according to their distribution among POI association scores from 1 (low) to 8 (high) and related
functional categories.
Figure 3 Case-control statistical analysis. (A) Pearson Chi-q test. Signiﬁcant P-values (<0.05) are in bold. (B)Wilcoxon rank sum test without
continuity correction. Mean and standard deviation (SD) are represented for both cases and controls. Signiﬁcant P-values (<0.05) are in bold. (C and
D) Ideogram view showing the results of Chi-q and Wilcoxon tests, respectively.
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reading frame is unaffected and that wild-type Tp63 protein is com-
posed of 680 aa, the hypothetical aberrant protein might be formed by
1109 aa (Fig. 4F).
Although 11 CNVs might be perturbed by position effect, we
focused our attention on deletion at 9p24.2 in POI-44 because it
involves the high score gene VLDLR and patient mRNA was available
Figure 4 Molecular characterization of TP63 gene duplication. (A) array-CGH proﬁle output. (B) Duplication view according to UCSC gen-
ome browser; intragenic duplication is represented by a blue bar from IVS1 to IVS9. (C) TP63 isoforms are shown with the respective duplicated por-
tion of 161 kb based on array-CGH results. (D) Duplication breakpoint characterization on gDNA performed by LR-PCR and sequencing with speciﬁc
primers for the duplicated allele is shown (direct tandem orientation is considered); an overlapping sequence of 11 bp between the breakpoint junc-
tions in IVS11 and IVS1 is shown. (E) Wild-type mRNA and mutated transcript with the relative sequences are shown. RT-qPCR analysis revealed a
statistically signiﬁcant TP63 overexpression in patients compared to controls which is indicative of the amount of the aberrant transcript. (F) Wild-type
and hypothetical aberrant Tp63 proteins are shown.
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for further studies. Array-CGH analysis revealed a four-probe deletion
of about 14.6 kb (chr9:2654,203-2668,811, hg19), involving VLDLR
3’UTR (NM_003383) and predicted regulatory elements (Fig. 5A and B).
LR-PCR and sequencing revealed that the VLDLR gene was preserved
conﬁrming a deletion of 12.4 kb (chr9:2656,920-2669,483, hg19)
(Fig. 5B). Through luciferase assays, the region containing the predicted
Figure 5 Molecular characterization of 9p24.2 deletion. (A) array-CGH proﬁle output. (B) Deletion view according to UCSC genome
browser; deletion is represented by a red bar from VLDLR 3’UTR to downstream. Primers used for LR-PCR analysis are shown and the relative output
is enlarged below the red bar. Regulatory elements included are shown (E1, E2, enhancers; INS, insulator). (C) Luciferase assay experiments using
both HeLa and COV434 cell lines. Ideograms showing the chemiluminescent emission for each construct are depicted. (D) RT-qPCR analysis high-
lighted in patient a dramatic downregulation of VLDLR mRNA compared to the average of controls. (E) The heterozygosity assay speciﬁc for rs6148 in
VLDLR exon 14 showed a mono-allelic expression.
580 Bestetti et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/34/3/574/5303711 by U
niversità degli Studi di M
ilano user on 18 April 2019
insulator and the 3000 bp downstream (INS-BglII) showed a strong spe-
ciﬁc enhancer effect in COV434, and particularly on the VLDLR promoter
(Fig. 5C). Indeed, RT-qPCR performed on patient peripheral blood
cDNA revealed a signiﬁcant transcript downregulation (P < 0.001;
Fig. 5D). Accordingly, the identiﬁcation on the patients’ DNA of a hetero-
zygous SNP (rs6148) in the coding region, highlighted mono-allelic mRNA
expression (Fig. 5D).
Regarding the intronic duplication at Xq21.33 involving DIAPH2
IVS26 and the entire long non-coding RNA (DIAPH2-antisense), RT-
qPCR was performed on POI-6 blood mRNA to evaluate a possible
DIAPH2 alteration, but no mRNA level changes were detected in the
analyzed tissue (data not shown).
CNVs at 10q26.3 involving CYP2E1 and SYCE1 were identiﬁed in
patients and controls. Namely, a deletion in POI-60 and a duplication
in POI-9, POI-11, POI-17, POI-62, CTR_F003, CTR_F008,
CTR_F021, CTR_F053, CTR_F084, and CTR_F086. To evaluate any
differences between patients and controls SYCE1 duplication CNVs,
which might explain a different variant effect reﬂecting a diverse
phenotype, qPCR experiments were carried out to clarify SYCE1
5’UTR complete or partial involvement. The analyses revealed no dif-
ferences between POI patients and controls rearrangements
(Supplementary Fig. S2).
Discussion
We report an array-CGH study, carried out on a cohort of 67 46,XX
young patients with PA or OD, which identiﬁed both old and novel
(i.e. TP63 and VLDLR) potentially deleterious CNVs for ovarian func-
tion with a detection rate of 47.8%. The study carried out on a control
cohort conﬁrmed the rarity of identiﬁed variants and their possible
involvement in POI pathogenesis: it revealed a signiﬁcant enrichment
in the number of patients presenting ovary-related variants compared
to controls, and similarly in the number of ovary-related CNVs, genes
and high score genes (Fig. 3). Despite ovary-related rare CNVs being
identiﬁed also in controls, most of them likely do not exert any effect
on the gene content expression, thus being less deleterious rearrange-
ments compared to those of patients. In contrast, as previously
reported (Tsuiko et al., 2016), no differences in the number of
selected common variants were found between patients and controls
suggesting that common CNVs might enhance the POI burden in com-
bination with other variants (Fig. 3).
Besides the identiﬁcation of CNVs involving POI genes, such as
DIAPH2 and BMP15, we detected variants previously reported on POI
cohorts, supporting their contribution in disease pathogenesis
(Supplementary Fig. S1). Among them, the 15q25.2 deletion (POI 54),
involving the ovary-related genes CPEB1, BNC1, WHAMM, SH3GL3,
and BTBD1, was previously identiﬁed in ﬁve POI unrelated patients
(McGuire et al., 2011; Hyon et al., 2016; Tsuiko et al., 2016). Based on
the severe phenotype of most patients (PA or early SA), it can be
hypothesized that such a variant might contribute to an early onset of
POI and that CPEB1 can be considered a leading candidate for ovarian
failure because it is involved in synaptonemal complex formation dur-
ing oocyte maturation (Tay and Richter, 2001). The additional identiﬁ-
cation of a homozygous microdeletion involving CPEB1 IVS1 (POI-46)
further support its role in POI pathogenesis. The 15q25.2 region
seems a POI-speciﬁc locus as other ovary-related genes are included,
such as the high prioritized BNC1 which plays a role in mouse oocytes
differentiation and causes its knock-out mouse to be sub-fertile (Tian
et al., 2001).
The duplications at 6q27 (POI-53) and at 19p13.3 (POI-63) involv-
ing TBP and ZFR2, respectively, had been previously reported in single
cases (Norling et al., 2014; Tsuiko et al., 2016). TBP is essential for
mouse oocyte maturation (Gazdag et al., 2007; Sun et al., 2013),
whereas only expression in follicles is known for ZFR2, whose role in
the ovary is still unknown (Fig. 2).
Another reported CNV, of uncertain signiﬁcance because it was
shared between patients and controls (Supplementary Fig. S1), was
the duplication encompassing the STS gene which is involved in the
steroidogenesis (Otsuka et al., 2005). Besides its previous identiﬁca-
tion in two SA patients (Quilter et al., 2010; Tsuiko et al., 2016), the
evidence of the same CNV in controls highlights its unclear role in POI
pathogenesis.
Deletions or duplications at 10q26.3 encompassing SYCE1 gene
(Supplementary Fig. S2) had been previously reported in several POI
cohorts (McGuire et al., 2011; Zhen et al., 2013; de Vries et al., 2014;
Jaillard et al., 2016; Tsuiko et al., 2016). SYCE1 plays a role in the syn-
aptonemal complex stability during meiosis (Costa et al., 2005) and its
haploinsufﬁciency in mouse causes oocytes apoptosis and infertility
(Bolcun-Filas et al., 2009). In humans, a nonsense homozygous muta-
tion in the SYCE1 gene, observed in two POI sisters might have a simi-
lar effect (de Vries et al., 2014). Supporting its pathogenic role, we
found the SYCE1 deletion only in patients (POI-60) but not among
controls, conﬁrming a frequency (1.49%) similar to that previously
reported (Tsuiko et al., 2016). Conversely, SYCE1 duplication was
found with a similar frequency among patients and controls (5.97%
and 4.48%, respectively) and should not have any POI susceptibility
role.
Our array-CGH analysis and the prioritization method uncovered
‘high score genes’ such as TP63 (3q28) and VLDLR (9p24.2). TP63
encodes a protein belonging to the p53 family and point mutations are
associated in autosomal dominant manner with a wide phenotypic
spectrum (OMIM#603273) including ADULT and Rapp-Hodgkin syn-
dromes. In sisters, POI-8 and POI-9 no TP63-phenotypes were
observed probably due to a different genetic defect. What is consist-
ent with their POI disorder, is that TP63 turns out to be a main regula-
tor of female germ cells genomic integrity during meiotic arrest (Suh
et al., 2006) and its knockout mice are infertile because oocytes do
not undergo apoptosis after DNA damage (Deutsch et al., 2011; Kim
and Suh, 2014). Indeed, TP63 intragenic duplications, affecting the
main functional domain of the protein (p-53 DNA binding domain),
give rise to a stable aberrant mRNA in patients, and consequently a
reduction of Tp63 activity might have deleterious effects on the oogen-
esis through an impaired function on genome integrity maintenance.
Interestingly POI-8 and POI-9 are also carriers of a predicted probably
damaging BMP15 heterozygous mutation (p.Y235C) (Di Pasquale
et al., 2004), and we propose that the combination of TP63 and
BMP15 alterations contributes to the ovarian dysgenesis seen in both
sisters, consistent with the recently reported oligogenic architecture of
early onset POI (Bouilly et al., 2016).
VLDLR in humans is relevant for steroidogenesis as its expression in
granulosa cells of pre-ovulatory follicles retains a relevant role in lipo-
protein endocytosis during follicular growth (Murata et al., 1998).
Moreover, in hens with VLDLR point mutations, the oocytes fail to
grow and therefore undergo atresia causing anovulation and sterility
581Identiﬁcation of new POI genes by array-CGH analysis
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/34/3/574/5303711 by U
niversità degli Studi di M
ilano user on 18 April 2019
(Bujo et al., 1995). In POI-44, based on our results, the observed dele-
tion far (2.4 kb) from VLDLR 3’UTR mediates a position effect on the
gene, and consistent with its ovarian function, we propose that VLDLR
haploinsufﬁciency could alter cholesterol endocytosis in the ovary
leading to an impaired folliculogenesis.
Although further functional studies are needed to clarify and prove
TP63 and VLDLR involvement on POI phenotype, the whole of these
array-CGH data identiﬁed novel pathogenic mechanisms for POI and
supported the extremely wide genetic heterogeneity of this disease.
The combination of extremely and moderately rare variants in an indi-
vidual patients conﬁrms that the oligogenic architecture can frequently
underlie POI with PA or an early age at onset. In such a context, the
combination of array-CGH with next generation sequencing repre-
sents the most suitable approach to obtain a comprehensive genetic
characterization of POI patients.
Supplementary data
Supplementary data are available at Human Reproduction online.
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